Trials / Completed
CompletedNCT03129594
Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction
Prognostic Value of Plasma Glucagon-like Peptide-1 Levels in Acute Myocardial Infarction
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 709 (actual)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | plasma glucagon-like peptide-1 levels | The plasma GLP-1 levels was determined by enzymatic assays. |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2017-04-26
- Last updated
- 2017-10-04
Source: ClinicalTrials.gov record NCT03129594. Inclusion in this directory is not an endorsement.